Recently, clinical studies have shown that SGLT2 inhibitors can remarkably prevent DKD progression and the onset of end-stage renal disease independent of lowering glucose (17, 18) and, thus, as SGLT2 inhibitors, Canagliflozin and Dapagliflozin (DAPA) have been used to delay the development of DKD (19). Here, SLC5A2 is linked to diabetic kidney disease.